Ratings Arctic Bioscience

Equities

ABS

NO0010859580

Market Closed - Oslo Bors Other stock markets 08:15:00 08/05/2024 pm IST			5-day change	1st Jan Change
10.4 ^NOK	0.00%		+6.12%	-0.95%

01/03	Arctic Bioscience AS Reports Earnings Results for the Full Year Ended December 31, 2023	CI
01/03	Transcript : Arctic Bioscience AS, Q4 2023 Earnings Call, Mar 01, 2024

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ARCTIC BIOSCIENCE	-0.95%	24.2M	-
ELI LILLY AND COMPANY	+32.36%	698B	C+
NOVO NORDISK A/S	+26.51%	568B	B
JOHNSON & JOHNSON	-4.40%	358B	C+
MERCK & CO., INC.	+19.46%	328B	B-
ABBVIE INC.	+3.50%	283B	C+
ASTRAZENECA PLC	+16.34%	238B	B+
NOVARTIS AG	+6.68%	203B	B-
ROCHE HOLDING AG	-9.08%	198B	A+
AMGEN INC.	+8.62%	165B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes